Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

CStone Announces Hong Kong Approval of Precision Medicine for GIST

publication date: Dec 28, 2021

Suzhou CStone Pharma announced Ayvakit ® (avapritinib) was approved in Hong Kong to treat gastrointestinal stromal tumors (GIST) harboring a PDGFRA D842V mutation. Ayvakit is a first-in-class precision therapy that will be used in adult patients with unresectable or metastatic GIST. The product is already approved for use in China. The Hong Kong Department of Health based the approval on a Phase I trial that showed an overall response rate 95%. In 2018, CStone acquired China rights to Ayvakit in a three-drug $386 million agreement. More details....

Stock Symbol: (HK: 2616)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.